SCHEMBL18579883

SCHEMBL18579883

O=C(O)COc1ccc(Oc2cnc3cc(Cl)ccc3n2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
CYP1A2 P05177 3/20 0.55
MAPT P10636 3/20 0.55
CYP3A4 P08684 2/20 0.55
LMNA P02545 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
HPGD P15428 2/20 0.55
NPSR1 Q6W5P4 2/20 0.55
TP53 P04637 1/20 0.55
ALOX15 P16050 1/20 0.55
NFKB1 P19838 1/20 0.55
HIF1A Q16665 1/20 0.55
GMNN O75496 1/20 0.55
APEX1 P27695 1/20 0.55
PMP22 Q01453 1/20 0.55
HTT P42858 7/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
CYP2C19 P33261 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27259682 0.95 ALDH1A1 (0.60) ALDH1A1CYP1A2MAPTCYP3A4LMNA
SCHEMBL9410481 0.90 ALDH1A1 (0.55) ALDH1A1CYP1A2MAPTCYP3A4LMNA
SCHEMBL18580142 0.89 CYP1A2 (0.54) ALDH1A1CYP1A2MAPTCYP3A4LMNA
SCHEMBL8299472 0.88 ALDH1A1 (0.53) ALDH1A1CYP1A2MAPTCYP3A4LMNA
SCHEMBL18580214 0.87 CYP1A2 (0.52) ALDH1A1CYP1A2MAPTCYP3A4LMNA
SCHEMBL18580631 0.87 CYP1A2 (0.54) ALDH1A1CYP1A2MAPTCYP3A4LMNA
SCHEMBL18580643 0.86 ALDH1A1 (0.54) ALDH1A1CYP1A2MAPTCYP3A4LMNA
SCHEMBL18580315 0.86 ALDH1A1 (0.53) ALDH1A1CYP1A2MAPTCYP3A4LMNA
SCHEMBL18580709 0.86 ALDH1A1 (0.53) ALDH1A1CYP1A2MAPTCYP3A4LMNA
SCHEMBL18580514 0.86 MAPT (0.53) ALDH1A1CYP1A2MAPTCYP3A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024132001-A1 MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) 2024-06-27 WO disclosed
US-20220098610-A1 NOVEL HERBICIDE RESISTANCE GENES DOW AGROSCIENCES LLC (US) 2022-03-31 US disclosed
US-20210254090-A1 NOVEL HERBICIDE RESISTANCE GENES DOW AGROSCIENCES LLC (US) 2021-08-19 US disclosed
US-11083717-B2 Compositions and methods for drug sensitization of parasites THE TEXAS A&M UNIVERSITY SYSTEM (US) 2021-08-10 US disclosed
US-11083717-B2 Compositions and methods for drug sensitization of parasites THE TEXAS A&M UNIVERSITY SYSTEM (US) 2021-08-10 US disclosed
US-10947555-B2 Herbicide resistance genes DOW AGROSCIENCES LLC (US) 2021-03-16 US disclosed
EP-3659597-A2 COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES The Texas A&M University System (US) 2020-06-03 EP disclosed
US-20200138796-A1 COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES THE TEXAS A&M UNIVERSITY SYSTEM 2020-05-07 US disclosed
US-20200138796-A1 COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES THE TEXAS A&M UNIVERSITY SYSTEM 2020-05-07 US disclosed
US-10543200-B2 Compositions and methods for drug sensitization of parasites THE TEXAS A&M UNIVERSITY SYSTEM (US) 2020-01-28 US disclosed
US-10543200-B2 Compositions and methods for drug sensitization of parasites THE TEXAS A&M UNIVERSITY SYSTEM (US) 2020-01-28 US disclosed
US-20190314381-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA THE TEXAS A&M UNIVERSITY SYSTEM 2019-10-17 US disclosed
US-20190314381-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA THE TEXAS A&M UNIVERSITY SYSTEM 2019-10-17 US disclosed
US-10300071-B2 Compositions and methods for inhibition of mycobacteria THE TEXAS A&M UNIVERSITY SYSTEM (US) 2019-05-28 US disclosed
US-10300071-B2 Compositions and methods for inhibition of mycobacteria THE TEXAS A&M UNIVERSITY SYSTEM (US) 2019-05-28 US disclosed
US-20180243275-A1 COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES THE TEXAS A&M UNIVERSITY SYSTEM 2018-08-30 US disclosed
US-20170065601-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA THE TEXAS A&M UNIVERSITY SYSTEM 2017-03-09 US disclosed
US-20170065601-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA THE TEXAS A&M UNIVERSITY SYSTEM 2017-03-09 US disclosed
US-20170065601-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA THE TEXAS A&M UNIVERSITY SYSTEM 2017-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10300071-B2 Compositions and methods for inhibition of mycobacteria ME3, PGLS, GNPAT ALDH1A1 1676/4885CYP1A2 706/4885MAPT 2084/4885
US-20180243275-A1 COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES ABCC1, SLC11A2, CYP3A43 ALDH1A1 886/4885CYP1A2 54/4885MAPT 3726/4885
US-20190314381-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA ME3, PGLS, GNPAT ALDH1A1 1676/4885CYP1A2 706/4885MAPT 2084/4885
US-20200138796-A1 COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES ABCC1, SLC11A2, ABCG2 ALDH1A1 839/4885CYP1A2 90/4885MAPT 3785/4885
US-10543200-B2 Compositions and methods for drug sensitization of parasites ABCC1, SLC11A2, ABCG2 ALDH1A1 839/4885CYP1A2 90/4885MAPT 3785/4885
US-11083717-B2 Compositions and methods for drug sensitization of parasites ABCC1, SLC11A2, ABCG2 ALDH1A1 839/4885CYP1A2 90/4885MAPT 3785/4885
US-20170065601-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA ME3, PGLS, GNPAT ALDH1A1 1676/4885CYP1A2 706/4885MAPT 2084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.